Olympus Corporation

Q3 miss / guidance trimmed (mainly U.S. execution in GI): Olympus revised FY revenue guidance (constant currency) down ~2%. Management said GI underperformance in Q3 was not due to declining competitiveness or clinician preference, but due to commercial execution—pipeline not converting in the U.S. They cited stronger engagement/interest, but insufficient conversion discipline by sales teams. Confidence for Q4 U.S. growth is tied to tighter pipeline management and KPIs (using a “China playbook” style of weekly oversight).

Range-based guidance: ship holds expected to resolve in Q4; no extra ship-hold assumption: The company introduced/maintained guidance ranges to reflect timing of recoveries and product re-releases. Management explicitly said the ranges do not anticipate additional ship holds; rather, sales could swing depending on when previously held products re-enter the market during Q4.

SIS ship holds & margin/gross margin pressure = one-offs; costs mostly inside the year: Management emphasized the SIS ship hold impact on revenue as significant (they referenced ~JPY 18bn revenue impact in Q4), but costs from disposal/recalls tied to ship holds were expected to largely end in Q3, with no additional cost of that type expected to flow into Q4. They also stated the gross margin decline was less about long-term mix and more about COGS impacts from ship-hold/field corrective actions, inventory disposal, and recall-related costs (described as one-off).